Eukles Asset Management Gilead Sciences, Inc. Transaction History

Eukles Asset Management

$244 Million
Q3 2024

A detailed history of Eukles Asset Management transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Eukles Asset Management holds 14,185 shares of GILD stock, worth $1.3 Million. This represents 0.49% of its overall portfolio holdings.

Number of Shares

14,185

Previous 14,436 1.74%

Holding current value

$1.3 Million

Previous $990,000 20.0%

% of portfolio

0.49%

Previous 0.44%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 29, 2024	SELL	$66.59 - $83.99 $16,714 - $21,081	-251 Reduced 1.74%	14,185 $1.19 Million
Q2 2024 Aug 01, 2024	SELL	$63.15 - $72.88 $10,798 - $12,462	-171 Reduced 1.17%	14,436 $990,000
Q1 2024 May 13, 2024	BUY	$71.58 - $87.29 $27,844 - $33,955	389 Added 2.74%	14,607 $1.07 Million
Q4 2023 Jan 31, 2024	SELL	$73.27 - $83.09 $34,363 - $38,969	-469 Reduced 3.19%	14,218 $1.15 Million
Q3 2023 Oct 25, 2023	BUY	$73.94 - $80.67 $6,284 - $6,856	85 Added 0.58%	14,687 $1.1 Million
Q2 2023 Aug 01, 2023	BUY	$76.01 - $86.7 $4,864 - $5,548	64 Added 0.44%	14,602 $1.13 Million
Q1 2023 Apr 28, 2023	SELL	$77.31 - $88.08 $4,715 - $5,372	-61 Reduced 0.42%	14,538 $1.21 Million
Q4 2022 Jan 27, 2023	BUY	$62.32 - $89.47 $45,119 - $64,776	724 Added 5.22%	14,599 $1.25 Million
Q3 2022 Oct 28, 2022	BUY	$59.54 - $68.01 $17,742 - $20,266	298 Added 2.19%	13,875 $856,000
Q2 2022 Jul 28, 2022	BUY	$57.72 - $65.01 $8,658 - $9,751	150 Added 1.12%	13,577 $839,000
Q1 2022 Apr 27, 2022	SELL	$57.92 - $72.58 $64,464 - $80,781	-1,113 Reduced 7.65%	13,427 $798,000
Q4 2021 Feb 10, 2022	SELL	$64.88 - $73.64 $19,723 - $22,386	-304 Reduced 2.05%	14,540 $1.06 Million
Q3 2021 Oct 28, 2021	SELL	$67.69 - $73.03 $2,775 - $2,994	-41 Reduced 0.28%	14,844 $1.04 Million
Q2 2021 Jul 27, 2021	BUY	$63.47 - $69.35 $50,141 - $54,786	790 Added 5.6%	14,885 $1.03 Million
Q1 2021 Apr 27, 2021	BUY	$60.0 - $68.46 $5,820 - $6,640	97 Added 0.69%	14,095 $911,000
Q4 2020 Jan 26, 2021	BUY	$56.65 - $64.55 $18,807 - $21,430	332 Added 2.43%	13,998 $816,000
Q3 2020 Oct 29, 2020	BUY	$62.1 - $78.08 $7,948 - $9,994	128 Added 0.95%	13,666 $864,000
Q2 2020 Jul 29, 2020	BUY	$72.34 - $84.0 $64,744 - $75,180	895 Added 7.08%	13,538 $1.04 Million
Q1 2020 Apr 22, 2020	SELL	$62.63 - $80.22 $40,083 - $51,340	-640 Reduced 4.82%	12,643 $945,000
Q4 2019 Jan 24, 2020	SELL	$61.62 - $67.78 $9,982 - $10,980	-162 Reduced 1.2%	13,283 $863,000
Q3 2019 Oct 29, 2019	SELL	$62.51 - $69.0 $2,687 - $2,967	-43 Reduced 0.32%	13,445 $852,000
Q2 2019 Aug 01, 2019	SELL	$61.87 - $69.38 $3,650 - $4,093	-59 Reduced 0.44%	13,488 $911,000
Q1 2019 Apr 23, 2019	BUY	$62.53 - $70.05 $4,189 - $4,693	67 Added 0.5%	13,547 $881,000
Q4 2018 Jan 22, 2019	BUY	$60.54 - $79.0 $816,079 - $1.06 Million	13,480 New	13,480 $843,000

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eukles Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Eukles Asset Management with notifications on news.

Account

Eukles Asset Management Gilead Sciences, Inc. Transaction History